Photocure with FDA Priority

Oslo Cancer Cluster member Photucure recently announced that the U.S. Food and Drug Administration (FDA) has accepted a Priority Review for an expansion of Cysview.

 

The FDA has accepted a supplemental New Drug Application (NDA) for Cysview on a priority review basis. Photocure, the Oslo, Norway-based company that developed and is marketing the drug-device system, wants to expand the labeling to include use for hospital patients not staying overnight.

Basically, a Priority Review  means that the FDA will speed up their approval process and a decision is now expected in the first half of 2018.

How Cysview Detects Cancer
Cysview is a method of detecting bladder cancer using photodynamic technology and is the only FDA approved product for use with blue light cystoscopy, where a device called a cystoscope is used to detect cancer inside the bladder.

Cysview is injected into the bladder through a catheter. It accumulates differentially in malignant cells. When illuminated with blue light from the cystoscope, the cancerous lesions fluoresce red, highlighting the malignant areas.

An important Tool
— Photocure is dedicated to improving the lives of patients with bladder cancer and we are committed to working with the FDA to bring this important clinical tool to the US market as soon as possible.

— We look forward to hearing a decision from the FDA early next year on the US Cysview® label expansion to include patients undergoing surveillance cystoscopy using a flexible scope, said Kjetil Hestdal, President & CEO, Photocure ASA.

 

 

 

About Photocure:

Photocure, the world leader in photodynamic technology, is a Norwegian based specialty pharmaceutical company. They develop and commercialize highly selective and effective solutions in several disease areas such as bladder cancer, HPV and precancerous lesions of the cervix and acne.

Their aim is to improve patient care and quality of life by making solutions based on Photocure Technology™ accessible to patients worldwide.

Photocure was founded by the Norwegian Radium Hospital in 1997. Today, the company, headquartered in Oslo, Norway, has over 60 highly skilled employees and operates in Norway, Sweden, Denmark, Finland and the United States.

Creating a SPARK in Innovation and Industry

Stanford programme SPARK provides a shimmer of hope for startup companies. Now, SPARK sets sights on Norway. What exactly is SPARK?

We live in a world where technological and innovative solutions in medicine and healthcare are steadily pouring in. Not to mention, these solutions have the power to completely transform the health-sector in pinpointing and curing diseases before they even take hold.

Why, then, is it that we have the power to revolutionize healthcare, but don’t see it happen?

Unfortunate answer
The unfortunate answer lies in the explanation that most of these technological and innovative solutions have a tough time reaching the bedside from the bench. Reason being lack of funding, marketing or other important factors that help an industry flourish. How can we resolve this?

A solution
Enter SPARK: the Stanford programme that provides a unique partnership between the industry and university.

SPARK provides the necessary factors that help start-up and small companies to advance research breakthroughs. This is done by providing the education and mentorship needed to move the project along further.

SPARK scholars
More specifically, it works by providing graduate level courses about drug-development processes as well as “SPARK Scholars”—funding for project development and mentoring. This mentoring is provided by advisors who have expertise in product development, business, clinical care and generally preparing participants for generating research into therapies.

Coming to Norway
The University of Oslo : Life Sciences is planning to bring Stanford’s programme to Norway where two other European SPARK-programmes have visited Oslo in the summer to share their experiences. One of the univesity’s candidates has tested the programme at summer-school in Japan, as well.

 

Innovative solutions
Oslo Cancer Cluster has been an advocate for SPARK’s involvement in Norway, along along with the Norwegian Inflammation Network (NORIN), The Life Science Cluster and Norway Health Tech (previously Oslo Medtech).

Jutta Heix, the international advisor at Oslo Cancer Cluster, comments on SPARK’s involvement:

–The SPARK programme really fills a gap in the lively and growing biopharma innovation system here in Norway and will help to advance more projects and ideas from academia into innovative solutions for patients. In collaboration with SPARK Berlin and SPARK Finland, SPARK Norway will also contribute to building a European SPARK Network providing even broader support, exposure and collaboration opportunities for the academic innovators involved.  

 

International Collaboration in Cancer Innovation

24 oncology innovators from 9 international hubs attended the 6th International Cancer Cluster Showcase in San Diego.

 

The International Cancer Cluster Showcase (ICCS) was born back in 2011 in Washington DC, during the world’s largest biotech conference, BIO International Convention. International cluster managers and representatives from the oncology field in Boston, Toulouse and Oslo met during a networking reception and agreed to team up for a joint initiative to expose their emerging oncology innovators to the global oncology community gathering at BIO.

This idea matured in a stimulating and dynamic annual meeting featuring oncology innovators from several North American and European innovation hubs.


Exciting partnering opportunities
During the  6th edition of ICCS around 200 delegates learned about exciting partnering opportunities pitched by 24 companies from 9 innovation hubs.

Oslo Cancer Cluster was represented by its member companies Oncoimmunity AS and Nordic Nanovector. The two companies presented their preclinical and clinical candidates for treating hematological cancers. Inven2, Norway’ largest tech transfer organisation, gave a glimpse into their growing oncology portfolio.

An overwhelming amount of cutting edge oncology innovations from leading North American and European industry clusters were presented in compact presentations. Poster sessions, networking parts and a final reception allowed the participants to connect and discuss collaboration opportunities.

– I hope that the ICCS 2017 reception was as productive for the participating biotechs as the BIO reception in Washington 6 years ago was for the founders of ICCS, said Jutta Heix, International Advisor at Oslo Cancer Cluster and coordinator for the event.

Our International Work

Oslo Cancer Cluster aims to enhance the visibility of oncology innovation made in Norway by being a significant partner for international clusters, global biopharma companies and academic centres.

– Our goal is to support our members in their effort to attract international partners, investments and successful academia-industry collaborations, says International Advisor Jutta Heix.

Heix is responsible for the cluster’s international initiatives, cluster network and partnering activities.

– Back in 2008, Oslo Cancer Cluster was not visible internationally, and few people knew about oncology innovation in Norway. We began to seek out partners and actively approach international pharma companies and other clusters offering relevant synergies, says Heix.


Building relationships abroad

The relationships thrive on joint initiatives. These include invitations to Norway with tailored programmes, where potential collaboration partners can meet academic teams, start-ups and biotechs. Oslo Cancer Cluster has also joined forces with other hubs and clusters internationally.

One such collaboration is the International Cancer Cluster Showcase (ICCS) at the global biotechnology gathering BIO International Convention in the US. In 2017, it is arranged for the 6th time, with European and North American partners, including the Massachusetts Technology Transfer Center, The Oncopole in Québec, The Wistar Institute in Philadelphia, Medicen in Paris and BioCat in Catalonia.

– This year the ICCS will showcase 24 innovative oncology companies from nine international innovation hubs and clusters. Three of our member companies in Oslo Cancer Cluster will use the opportunity to pitch their products and ideas to a global oncology audience, says Heix.

Jutta Heix is Oslo Cancer Cluster’s international advisor.


European and Nordic arenas
Meeting places are important in Europe too, with BIO-Europe, BIO-Europe Spring and Nordic Life Science Days at the top of the list. Oslo Cancer Cluster is the oncology partner at the Nordic Life Science Days. As a region, the Nordic countries are of international importance in the field of cancer research and innovation, especially in precision medicine, and Oslo Cancer Cluster participates in advancing Nordic collaboration.

Oslo Cancer Cluster also engages in more cancer specific European events. One example is the Association for Cancer Immunotherapy Meeting (CIMT), which is the largest European meeting in the field of cancer immunotherapy, also known as immuno-oncology.

– Many of our members are active in the field of immuno-oncology, so for a couple of years we have organized an event called CIMT Endeavour with German partners. The aim here is to discuss and promote translational research and innovation in immuno-oncology, says Heix.


Hot topics

Cancer immunotherapy has had a major impact on cancer treatment and global research and development in the cancer field. The concept took off with the approval of the first immune-checkpoint inhibitor, called Ipilimumab, in 2011. It offered a ground breaking new treatment for melanoma. In 2013, Science Magazine defined cancer immunotherapy as the breakthrough of the year. Since then, immunotherapy has been dominating the agenda of oncology meetings.

Other hot research and development topics are precision medicine and the increased digitization of the health sector. Oslo Cancer Cluster incorporates these topics in the international work, and aims to expand the services it provides for its members. The cluster recently got funding from Innovation Norway to do this, by adding an EU-advisor to the team.

– We want to increase our members’ involvement in EU’s research and innovation programme Horizon 2020. The new EU-advisor will help our members identify relevant funding schemes, find partners and prepare the applications, says Heix.

This initiative has already started to show some results. In the spring of 2017, Oslo Cancer Cluster member OncoImmunity AS won a prestigious Horizon 2020 SME Instrument grant, tailored for small and medium sized enterprises (SMEs). This grant targets innovative businesses with international ambitions — such as the bioinformatics company OncoImmunity.

 

New meeting places
– Member needs are important for us, as it is for clusters in general. Our network is for the benefit of our members. A good way of leveraging the network, is by creating relevant initiatives and new meeting places – to keep things moving forward, says Heix.

Oslo Cancer Cluster has new international initiatives coming up. One is in immuno-oncology, bringing Norwegian biotechs to the well-established research communities on the US East coast. The biotechs will get training and support, and will meet academic medical centres and biopharma companies in Boston and other cities. This initiative is supported by Innovation Norway’s Global Growth programme.

Another new initiative takes on academic innovation. More good ideas from academia should make it into patents, start-ups and investment opportunities for industry partners.

– Stanford University has a programme called SPARK. We are working with Norwegian partners, including The University of Oslo Life Science and The Norwegian Inflammation Network (NORIN), on implementing a Norwegian SPARK-programme. This will be part of the global SPARK-network, and we are already building a European node together with Berlin and Finland, Jutta Heix says.

OncoImmunity AS wins the EU SME Instrument grant

The bioinformatics company OncoImmunity AS was ranked fourth out of 250 applicants for this prestigious grant.

250 companies submitted proposals to the same topic call as OncoImmunity AS. Only six projects were funded.

We applied for the SME instrument grant as it represents an ideal vehicle for funding groundbreaking and innovative projects with a strong commercial focus. The call matched our ambition to position OncoImmunity as the leading supplier of neoantigen identification software in the personalised cancer vaccine market”, says Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity.


Personalised cancer vaccines
Neoantigen identification software facilitates effective patient selection for cancer immunotherapy, by identifying optimal immunogenic mutations (known as neoantigens). OncoImmunity develops proprietary machine-learning software for personalised cancer immunotherapy.

This solution also guides the design of neoantigen-based personalised cancer vaccines and cell therapies, and enables bespoke products to be developed faster.

The SME Instrument gives us the opportunity to further refine and optimise our machine-learning framework to facilitate personalised cancer vaccine design. This opportunity will help us establish the requisite quality assurance systems, certifications, and clinical validation with our partners, to get our software accredited as an in vitro diagnostic device”, says Dr. Richard Stratford.

In vitro diagnostics are tests that can detect diseases, conditions, or infections.

Dr. Richard Stratford is Chief Executive Officer and Co-founder of OncoImmunity, member of Oslo Cancer Cluster and part of the Oslo Cancer Cluster Incubator.


Hard to get
Horizon 2020’s SME Instrument is tailored for small and medium sized enterprises (SMEs). It targets innovative businesses with international ambitions — such as OncoImmunity.

“The SME instrument is an acid test; companies that pass the test are well suited to make their business global. It also represents a vital step on the way to building a world-class health industry in Norway”, says Mona Skaret, Head of Growth Companies and Clusters in Innovation Norway.

The SME Instrument has two application phases. Phase one awards the winning company 50 000 Euros based on an innovative project idea. Phase two is the actual implementation of the main project. In this phase, the applicant may receive between 1 and 2,5 million Euros.

The support from the SME instrument is proof that small, innovative Norwegian companies are able to succeed in the EU”, says Mona Skaret.

You can read more about the Horizon 2020 SME Instrument in Norwegian at the Enterprise Europe Network in Norway.

 

Thinking of applying?
Oslo Cancer Cluster helps its member companies with this kind of applications through the EU Advisor Program and close collaboration with Innovayt and Innovation Norway.

The SME Instrument is looking for high growth and highly innovative SMEs with global ambitions. They are developing innovative technologies that have the potential to disrupt the established value networks and existing markets.

Companies applying for the SME Instrument must meet the requirements set by the programme. Please see the SME Instrument website for more information.

Kick-Off: Call for Proposals for PERMIDES

The first call for proposals for the PERMIDES project is opening on March 15th. We urge all small and medium sized biopharma-companies working to take the step into the digital era, to apply for funding up to 60 000 Euros.

 

D.B.R.K Gupta Udatha, project manager for PERMIDES, is very happy to kick off the first call for proposals. He wants to help you succeed in this call for proposal by defining the essentials:

‘In your proposals, you should address the innovation barriers and challenges that you experience in the area of personalised medicine. It should be challenges that somehow can be solved by digitalisation’, says Udatha.

 

Developing novel personalised medicine
The voucher funding scheme of PERMIDES is aimed at small and medium sized enterprises (SMEs) from the biopharmaceutical sector developing novel personalised medicine products and solutions (e.g. biotech/medtech companies, diagnostics companies, CROs, biobank companies, bioinformatic companies).

‘To be eligible for funding, project teams must consist of one biopharma SME as the main applicant or beneficiary. In addition, there must be at least one IT SME as a service provider. Potential team partners in the project can be found via the PERMIDES platform, which offers a matchmaking of companies from the biopharmaceutical and IT sectors’, says Udatha.

 

Get more information:

 

Contact:

Jutta Heix, International Advisor
D.B.R.K Gupta Udatha, Project Manager PERMIDES

 

Kronikk i Aftenposten: De nordiske landene kan gjøre noe resten av verden drømmer om

De nordiske landene bør samarbeide mer for å utvikle bedre kreftbehandlinger. Sammen kan Norden bli et globalt forsknings- og testsenter for nye kreftbehandlinger og -medisiner. Det kan gi store gevinster for kreftpasienter i hele verden. Denne kronikken sto på trykk i Aftenposten torsdag 9. mars.

Ketil Widerberg, daglig leder i Oslo Cancer Cluster, skrev kronikken samme uke som The Economist, Forskningsrådet og Oslo Cancer Cluster arrangerte den nordiske konferansen War on Cancer Nordics i Oslo. De nordiske landene ønsker å lede an i kampen mot kreft. Nå er det på tide at infrastrukturer og lovverk legges til rette for det.


Norden kan vise vei i kampen mot kreft. For vi har noe de andre – selv ikke USA – har


Design, TV-serier og nå: kreft
Nordisk design er verdenskjent, og nordisk film har gjennom TV-serier som Broen etablert en ny sjanger i underholdningsindustrien. På 1990-tallet endret Nokia og Ericsson hvordan vi brukte mobiltelefonen. Slike fremskritt setter Norden på det internasjonale kartet og skaper arbeidsplasser. Nå er tiden inne for liknende fremskritt i kampen mot kreft. Vi har gode forutsetninger, men er vi vårt ansvar bevisst?

Vi har fremragende kreftforskning, for eksempel innen immunterapi for kreft, fotodynamisk teknologi og radioaktive legemidler (radiofarmaka). På disse områdene gjør både nordiske forskere og bioteknologifirmaer det godt internasjonalt. Hver for seg er de nordiske landene små, men samlet har de over 26 millioner innbyggere, og er et interessant marked for forskning, bioteknologi- og legemiddelselskaper.


Norden har unike fortrinn
Norden har flere forutsetninger for å lykkes. Først og fremst har alle nordiske borgere et unikt personnummer. Dette mangler faktisk i mange andre land, som USA. Personnummer har gjort det mulig for nordiske myndigheter å samle unike helsedata. I over 60 år har de nordiske landene samlet helse- og kreftdata i biobanker og registre og bygd verdensledende helsesystemer. Den nordiske befolkningen har dessuten et stort digitalt liv, og samfunnet har generell tillit til forskning.

De nordiske landene kan bruke disse felles fortrinnene til å gjøre noe resten av verden drømmer om: bruke offentlige helsedata for å se hvilken lovende medisin som virker på hver enkelt pasient. Slik kan legemiddelet godkjennes og tas i bruk før de tradisjonelle tidkrevende og kostbare delene av klinisk utprøving blir satt i gang. Tiden det tar fra et kreftlegemiddel blir patentert til det blir godkjent til bruk vil bli kortere, og pasienten vil kunne få behandlingen flere år tidligere. Samfunnet vil kunne spare millioner. Norden bør være seg sitt ansvar bevisst og gå i bresjen for raskere utvikling av ny kreftbehandling. Vi har ikke råd til å vente.


Ny viten gir bedre behandling
Kreft er en av vår tids store samfunnsutfordringer. Hvert år dør 8 millioner mennesker av kreft i verden og 14 millioner av oss får en kreftdiagnose. Det er mange, og antallet vil øke. Ifølge Verdens helseorganisasjon vil det øke med hele 70 prosent de neste 20 årene.

Heldigvis øker også forståelsen av hvor komplekse sykdommene som vi kaller kreft er. Vi vet at det finnes over 200 kreftsykdommer, og vi vet at kreft påvirkes blant annet av genetiske faktorer. I tillegg har vi nå forstått at immunsystemet spiller en viktige rolle i utviklingen av ulike kreftsykdommer og at vi kan påvirke immunsystemet til å spille på lag med kroppen mot kreften. Økt kunnskap om hva kreft egentlig er gir oss bedre forutsetninger for å vinne kampen mot kreft. Men med ny viten følger også en ny dynamikk for hvordan behandling skal utvikles, kategoriseres og tilbys pasienter.


Tid for politisk vilje
Digitalisering av kreftforskning gir rask fremgang i mange land. Store globale teknologifirmaer som Microsoft, IBM og Google satser nå på helse, og spesifikt kreft. Med kunstig intelligens kan kreftforskere simulere, teste hypoteser og samle og korrelere data som ikke var mulig for kun få år siden. Norden har unike helsedatabaser, og vi kan bygge opp kompetanse sammen med globale selskaper på samme måte som Norge bygde opp oljeindustrien på 1970-tallet. Da inviterte Norge inn store internasjonale selskaper som utviklet oljeindustrien under statlig styring. Dette krevde samarbeid og tilrettelegging fra det offentlige.

En satsing på et nordisk kreftsamarbeid krever også offentlig tilrettelegging. Myndighetene og offentlige instanser må åpne for at forskere kan få bruke helsedataene vi allerede har. I Norden har vi strukturen som gjør det mulig å nå raskere fram med ny forskning. Vi kan hjelpe pasienter ved å godkjenne og ta i bruk legemidler før de tradisjonelle tidkrevende og dyre siste kliniske studiene settes i gang. Både USA og EU har forsøkt, men med begrenset hell, blant annet fordi de mangler personnummer og har fragmenterte helsesystemer. Der har de politisk vilje, men mangler strukturene.


Et globalt testsenter
Nordiske helsevesen samler inn stadig mer data fra befolkningen. Nå kan slike helsedata brukes til å utvikle medisiner raskere. Det vil stille nye krav til rapportering, sikkerhet og formål med bruk av helsedata. Det vil kreve en åpen og innovativ holdning både fra offentlige og private aktører. Dette er ikke risikofritt, men gevinsten for samfunnet og for den enkelte pasient som overlever takket være raskere og bedre behandling, vil være betydelig.

Norden har en unik mulighet til å være et globalt testsenter for utvikling av nye legemidler som utnytter den offentlige digitale infrastrukturen. Google endret hvordan vi bruker internettet. Vi gikk fra AltaVista til Google, og så oss aldri tilbake. Norden har alle forutsetninger for å lede an i digitaliseringen innen helse. Det kan være med på å endre livet til de 14 millionene nye menneskene som får kreft hvert år.

Ketil Widerberg, daglig leder i Oslo Cancer Cluster

Targovax to present at upcoming conferences

Oslo, Norway, 6 March 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:

 

10th European Life Science CEO Forum (hosted by Sachs Associates)
Date: 7 March 2017
Venue: Hilton Zurich Airport Hotel, Zurich, Switzerland

Panel discussion time: 11:10 CET – Advances in Immuno-Oncology Therapeutics Panel

– Magnus Jäderberg (CMO)

Presentation time: 12:25 CET

– Øystein Soug (CEO)

 

Redeye – Fight Cancer Seminar
Date: 10 March 2017
Venue: Redeye, Stockholm, Sweden

Presentation time: 10:50 CET

Participants: Øystein Soug (CEO)

 

11th Annual BIO-Equity Spring 2017 Conference
Date: 20-22 March 2017
Venue: CCIB Convention Centre in Barcelona, Spain

Participants: Øystein Soug (CEO) and Peter Skorpil (VP Business Development)

 

The presentations will be available to download at www.targovax.com following these events.

 

For further information, please contact:

Renate Birkeli, Investor Relations

Phone: +47 922 61 624

Email: renate.birkeli@targovax.com

 

Media and IR enquires:

Jan Petter Stiff – Crux Advisers (Norway)

Phone: +47 995 13 891

Email: stiff@crux.no

 

Julia Phillips/Simon Conway – FTI Consulting (International)

Phone: +44 20 3727 1000

Email: Targovax@fticonsulting.com

 

About Targovax

Arming the patient’s immune system to fight cancer

Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

The Company’s development pipeline is based on two novel proprietary platforms:

The first platform, ONCOS, uses oncolytic viruses, an emerging class of biological therapy. ONCOS exclusively uses an adenovirus that has been engineered to be a tumor-targeted immune activator. The platform has the potential to generate therapies with superior efficacy and safety compared to the first approved oncolytic virus therapy, Imlygic®, launched by Amgen. We continue to expect key proof of concept data for this platform in 2017 from a clinical study of lead program ONCOS-102 in patients with refractory malignant melanoma.

The second platform, TG-Peptides (TGP), solely targets tumors that express mutated forms of the RAS protein. Mutations to this protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations.  The TGP platform’s therapeutic potential stems from its ability to enable a patient’s immune system to identify and then destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TGP platform from a clinical study of TG01 in resected pancreatic cancer patients showed encouraging overall survival and will determine plans for the future clinical development of this platform.

Targovax’s development pipeline has three novel therapeutic candidates in clinical development covering six indications. Already promising safety and tolerability data and early signs of clinical response have been demonstrated.

Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. We have a number in early stages of development in addition to the three outlined above.

In July, 2016 the Company listed its shares on Oslo Axess.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

The Economist & Oslo Cancer Cluster: War on Cancer Nordics

Oslo Cancer Cluster is proud to be partner of The Economist Events War On Cancer Nordics.

The War on Cancer Nordics 2017 in Oslo will gather leaders in oncology from the Nordic region and beyond, to discuss the region’s primary challenges in cancer care and control. The event will bring together policy makers, NGOs, academia, research and health care professionals, patient groups and cancer control institutes with private sector business leaders.

 

Questions we will answer

  • How much does cancer cost the Nordic countries per year both in terms of treatment costs and its impact on the labour market?
  • Would a unified Nordic oncology framework be desirable? 
  • What can be learnt from countries that have made more progress in prevention initiatives? 
  • How could research in immuno-oncology be scaled across the region to improve outcomes for patients? 
  • What role will new technologies play in shaking up cancer care, from prevention, through diagnosis, to treatment and to optimise symptoms and quality of life?

 

Founding sponsor: The Research Council og Norway and silver sponsor: Roche

Dehns is now member of the Oslo Cancer Cluster

Dehns Patent and Trade Mark Attorneys recently joined the Oslo Cancer Cluster.

Dehns is one of Europe’s largest firms of patent and trade mark attorneys and has a 40 year history of working with Norwegian organisations such as: Dynal, Inven2,Lytix Biopharma, Nextera, NMBU, NTNU, Nycomed, PCI Biotech and Photocure.

As members, our aim is to advise and help protect the other members needs regarding innovations and intellectual property (IP) around cancer research, diagnosis and treatment.

With experts in this field, many of whom also have PhDs, we can help you build and manage your IP portfolio and strategy, including providing advice on the patentability of inventions, draft and file patent applications, represent you in opposition and other contentious proceedings, as well as advise on academia-industry collaborations and licensing agreements.

www.dehns.com